Target Name: PLAT
NCBI ID: G5327
Review Report on PLAT Target / Biomarker Content of Review Report on PLAT Target / Biomarker
PLAT
Other Name(s): OTTHUMP00000225785 | Tissue plasminogen activator | Plasminogen activator, tissue type, transcript variant 1 | Tissue-type plasminogen activator chain A | T-plasminogen activator | plasminogen/activator kringle | Tissue-type plasminogen activator (isoform 1) | PLAT variant 1 | Tissue-type plasminogen activator chain B | t-PA | plasminogen activator, tissue type | alteplase | T-PA | OTTHUMP00000225786 | OTTHUMP00000225788 | Tissue plasminogen activator (t-PA) | reteplase | PLAT variant 3 | Tissue-type plasminogen activator | OTTHUMP00000225783 | TPA | Tissue-type plasminogen activator (isoform 3) | TPA_HUMAN | Reteplase | OTTHUMP00000225787 | Plasminogen activator, tissue type, transcript variant 3 | Alteplase | OTTHUMP00000225784 | DKFZp686I03148 | t-plasminogen activator | Plasminogen activator, tissue type | tPA

PLAT: A Drug Target / Disease Biomarker

PLAT is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a scaffold protein that helps to maintain the structure and stability of the blood vessels. PLAT has also been shown to play a role in the regulation of inflammation and has potential as a drug target or biomarker.

One of the key functions of PLAT is its role in the regulation of blood vessel integrity. PLAT helps to maintain the structure and stability of the endothelial cell, which forms the lining of the blood vessels. This is important for the proper functioning of the blood vessels, as they are responsible for delivering oxygen and nutrients to the body's cells and for removing waste products.

In addition to its role in blood vessel integrity, PLAT has also been shown to play a key role in the regulation of inflammation. Inflammation is a natural response of the immune system, but when it becomes chronic or excessive, it can cause a range of health problems, including chronic pain, heart disease, and cancer. PLAT has been shown to help to regulate the production of pro-inflammatory molecules, which are important for the start of the inflammatory response.

This is important because PLAT has the potential to be used as a drug target or biomarker for a variety of conditions that are characterized by chronic inflammation. For example, PLAT has been shown to be involved in the development of chronic pain, including osteoarthritis and rheumatoid arthritis. It has also been shown to be involved in the development of heart disease and cancer, which are two of the leading causes of death and disability in the world.

In addition to its potential as a drug target or biomarker, PLAT is also of interest as a potential therapeutic agent for treating a variety of conditions. For example, PLAT has been shown to be effective in animal models for treating inflammation-related conditions, including rheumatoid arthritis and chronic pain. It is also being investigated as a potential therapeutic for treating a variety of other conditions, including heart disease, cancer, and neurodegenerative diseases.

Overall, PLAT is a protein that has the potential to be a drug target or biomarker for a variety of conditions that are characterized by chronic inflammation. Further research is needed to fully understand its role and potential therapeutic applications.

Protein Name: Plasminogen Activator, Tissue Type

Functions: Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. During oocyte activation, plays a role in cortical granule reaction in the zona reaction, which contributes to the block to polyspermy (By similarity)

The "PLAT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLAT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Platelet Glycoprotein Ib Complex | Platelet-activating factor acetylhydrolase isoform 1B complex | Platelet-Derived Growth Factor (PDGF) | Platelet-Derived Growth Factor Receptor | PLAU | PLAUR | PLB1 | PLBD1 | PLBD1-AS1 | PLBD2 | PLCB1 | PLCB2 | PLCB3 | PLCB4 | PLCD1 | PLCD3 | PLCD4 | PLCE1 | PLCE1-AS2 | PLCG1 | PLCG1-AS1 | PLCG2 | PLCH1 | PLCH2 | PLCL1 | PLCL2 | PLCXD1 | PLCXD2 | PLCXD3 | PLCZ1 | PLD1 | PLD2 | PLD3 | PLD4 | PLD5 | PLD6 | PLEC | PLEK | PLEK2 | PLEKHA1 | PLEKHA2 | PLEKHA3 | PLEKHA4 | PLEKHA5 | PLEKHA6 | PLEKHA7 | PLEKHA8 | PLEKHA8P1 | PLEKHB1 | PLEKHB2 | PLEKHD1 | PLEKHF1 | PLEKHF2 | PLEKHG1 | PLEKHG2 | PLEKHG3 | PLEKHG4 | PLEKHG4B | PLEKHG5 | PLEKHG6 | PLEKHG7 | PLEKHH1 | PLEKHH2 | PLEKHH3 | PLEKHJ1 | PLEKHM1 | PLEKHM1P1 | PLEKHM2 | PLEKHM3 | PLEKHN1 | PLEKHO1 | PLEKHO2 | PLEKHS1 | PLET1 | Plexin | PLG | PLGLA | PLGLB1 | PLGLB2 | PLGRKT | PLIN1 | PLIN2 | PLIN3 | PLIN4 | PLIN5 | PLK1 | PLK2 | PLK3 | PLK4 | PLK5 | PLLP | PLN | PLOD1 | PLOD2 | PLOD3 | PLP1 | PLP2 | PLPBP | PLPP1 | PLPP2